Key Details
Price
$1.95Annual ROE
-45.90%Beta
0.47Events Calendar
Next earnings date:
Mar 07, 2025Recent quarterly earnings:
Nov 07, 2024Recent annual earnings:
Mar 07, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Feb 16, 1994Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
Research Frontiers Incorporated (NASDAQ:REFR ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Joe Harary - President and CEO Operator Good afternoon, ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Third Quarter of 2024 Results of Operations and Recent Developments [Operator Instructions].
WOODBURY, NY, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR ) announced today that it will release its third quarter 2024 financial results on Thursday, November 7, 2024. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, November 7, 2024 to discuss its third quarter 2024 financial and operating results, as well as recent developments.
SOUTH SAN FRANCISCO, Calif., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-P1, the registration-directed study of luveltamab tazevibulin (luvelta) for pediatric patients with CBFA2T3::GLIS2 (CBF/GLIS; RAM phenotype) acute myeloid leukemia (AML), has been initiated and is open for enrollment.
SOUTH SAN FRANCISCO, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that REFRαME-L1, the global Phase 2 study of luveltamab tazevibulin (luvelta) for patients with non-small cell lung cancer (NSCLC) whose tumor expresses Folate Receptor-α (FRα), has been initiated and is open for enrollment. Initial data from this study is expected in the first half of 2025.
Research Frontiers, Inc. (NASDAQ:REFR ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Joe Harary - President & CEO Conference Call Participants Neal Goldman - Goldman Capital Management Michael Kay - Kay Associates Leonard Lietzow - Private Investor Jeff Harvey - Private Investor Allen Ginsberg - Private Investor Operator Good afternoon ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Second Quarter of 2024 results of operations and recent developments.
WOODBURY, N.Y., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR ) announced its financial results for its second quarter of 2024. Management will host a conference call today at 4:30 p.m. Eastern Time to discuss its financial and operating results as well as recent developments.
WOODBURY, NY, July 29, 2024 (GLOBE NEWSWIRE) -- Research Frontiers Inc. (Nasdaq: REFR ) announced today that it will release its second quarter 2024 financial results on Thursday, August 1, 2024. Research Frontiers will host a conference call at 4:30 p.m. Eastern Time on Thursday, August 1, 2024 to discuss its second quarter 2024 financial and operating results, as well as recent developments.
Research Frontiers Incorporated (NASDAQ:REFR ) Q4 2023 Earnings Conference Call March 7, 2024 4:30 PM ET Company Participants Joe Harary – President and Chief Executive Officer Conference Call Participants Ted Campbell – Private Investor Alan Ginsberg – Private Investor Gerald Sherman – Strategic Planning Group Art Brady – Private Investor John Nelson – Private Investor August Berman – Private Investor Mike Zelnick – Private Investor Bruce Denny – Private Investor Jeff Harvey – Private Investor Seth Nickerson – Private Investor Operator Good afternoon, ladies and gentlemen. Welcome to Research Frontiers Investor Conference Call to discuss the Fourth Quarter and Full Year 2023 Results of operations and recent developments.
Research Frontiers Incorporated (NASDAQ:REFR ) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Joseph Harary - President and CEO Conference Call Participants Operator Good afternoon, ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the Second Quarter of 2023 Results of Operations and recent developments.
Research Frontiers Incorporated (NASDAQ:REFR ) Q1 2023 Results Conference Call May 4, 2023 4:30 PM ET Company Participants Joe Harary - President and CEO Conference Call Participants Jared Sherman - Strategic Planning Group Operator Good afternoon, ladies and gentlemen. Welcome to the Research Frontiers Investor Conference Call to discuss the first quarter of 2023 results of operations and recent developments.
FAQ
- What is the primary business of Research Frontiers Incorporated?
- What is the ticker symbol for Research Frontiers Incorporated?
- Does Research Frontiers Incorporated pay dividends?
- What sector is Research Frontiers Incorporated in?
- What industry is Research Frontiers Incorporated in?
- What country is Research Frontiers Incorporated based in?
- When did Research Frontiers Incorporated go public?
- Is Research Frontiers Incorporated in the S&P 500?
- Is Research Frontiers Incorporated in the NASDAQ 100?
- Is Research Frontiers Incorporated in the Dow Jones?
- When was Research Frontiers Incorporated's last earnings report?
- When does Research Frontiers Incorporated report earnings?